Drug Type Fusion protein |
Synonyms hsIgG, Hypersialylated IgG, Hypersialylated immunoglobulin + [2] |
Target- |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | US | 28 Jan 2019 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | BE | 28 Jan 2019 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | FR | 28 Jan 2019 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | DE | 28 Jan 2019 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | HU | 28 Jan 2019 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | IT | 28 Jan 2019 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | NL | 28 Jan 2019 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | PL | 28 Jan 2019 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | ES | 28 Jan 2019 | |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 1 | US | 11 Jan 2020 |